


Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Aug-2023
Document Type: USP Monographs
DocId: GUID-0ADF040B-2AEC-400F-AA78-B75058D9FB78_6_en-US
DOI: https://doi.org/10.31003/USPNF_M27770_06_01
DOI Ref: 9t58r

© 2025 USPC
Do not distribute

Dobutamine Hydrochloride

Change to read:



$C_{18}H_{23}NO_3 \cdot HCl$ 337.84

1,2-Benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, hydrochloride, (±)-;

(±)-4-[2-[[3-(*p*-Hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride CAS RN®: 49745-95-1; ▲UNII: 0WR771DJXV.▲ (USP 1-Aug-2023)

DEFINITION

Dobutamine Hydrochloride contains NLT 98.0% and NMT 102.0% of dobutamine hydrochloride ($C_{18}H_{23}NO_3 \cdot HCl$), calculated on the anhydrous basis.

[CAUTION—Great care should be taken to prevent inhaling particles of dobutamine hydrochloride and exposing the skin to it. Protect the eyes.]

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: 197A or 197K
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Delete the following:

- ▲ **C.** **CHLORIDE**▲ (USP 1-Aug-2023)

Add the following:

- ▲ **C.** [IDENTIFICATION TESTS—GENERAL \(191\)](#), *Chemical Identification Tests, Chloride*

Sample solution: 50 mg/mL of Dobutamine Hydrochloride in a mixture of [water](#) and [methanol](#) (50:50)

Analysis: Proceed as directed in the chapter using the procedure for amine hydrochlorides, except wash the precipitate with three 1-mL portions of [water](#).

Acceptance criteria: Meets the requirements of the test for amine hydrochlorides▲ (USP 1-Aug-2023)

ASSAY

Change to read:

• PROCEDURE

Solutions containing dobutamine hydrochloride must be prepared fresh at the time of use and refrigerated until injected.

Solution A: Transfer 23 g of [monobasic ammonium phosphate](#) to a 2-L volumetric flask, and add 1900 mL of [water](#). Adjust with [phosphoric acid](#) to a pH of 2.2, and dilute with [water](#) to volume.

Mobile phase: [Acetonitrile](#) and *Solution A* (20:80)

Standard solution: 0.5 mg/mL of [USP Dobutamine Hydrochloride RS](#) in [water](#)

Sample solution: 0.5 mg/mL of Dobutamine Hydrochloride in [water](#)

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 280 nm

Column: 3.9-mm × 30-cm; 15–20-μm packing [L1](#). ▲[NOTE—Alternatively, a column with 10-μm particle size may be used.]▲ (USP 1-Aug-2023)

Flow rate: 1.5 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of dobutamine hydrochloride ($C_{18}H_{23}NO_3 \cdot HCl$) in the portion of Dobutamine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of dobutamine from the *Sample solution*

r_S = peak response of dobutamine from the *Standard solution*

C_S = concentration of [USP Dobutamine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Dobutamine Hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the anhydrous basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.2%

Change to read:

- **ORGANIC IMPURITIES**

Solution A: 2.6 g/L of [sodium 1-octanesulfonate](#) in [water](#). Pipet 3 mL of [triethylamine](#) into 1 L of this solution. Adjust the solution with [phosphoric acid](#) to a pH of 2.5.

Solution B: [Methanol](#) and [acetonitrile](#) (82:18)

Diluent: *Solution A* and *Solution B* (50:50)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	65	35
5	65	35
20	20	80
25	20	80
26	65	35
30	65	35

Sensitivity solution: 1.25 µg/mL of [USP Dobutamine Hydrochloride RS](#) in *Diluent*

Standard solution: 0.025 mg/mL each of [USP Dobutamine Related Compound C RS](#), [USP Dopamine Hydrochloride RS](#), and [USP Raspberry Ketone RS](#); and 0.005 mg/mL of [USP Dobutamine Hydrochloride RS](#) in *Diluent*

Sample solution: 5 mg/mL of Dobutamine Hydrochloride in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 280 nm

Column: 4.6-mm × 15-cm; 5-µm packing [L1](#)

Flow rate: 1 mL/min

Injection volume: 20 µL

System suitability

Samples: *Sensitivity solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.5 between dopamine and raspberry ketone, *Standard solution*

Tailing factor: NMT 2.0 for dobutamine, *Standard solution*

Relative standard deviation: NMT 2.0% for dobutamine, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of ▲dopamine, raspberry ketone, and dobutamine related compound C▲ (USP 1-Aug-2023) in the portion of Dobutamine Hydrochloride taken:

Result = (r_U/r_S) × (C_S/C_U) × 100

r_U = peak response of ▲dobutamine related compound C, dopamine, and raspberry ketone▲ (USP 1-Aug-2023) from the *Sample solution*

r_S = peak response of ▲dobutamine related compound C, dopamine, and raspberry ketone▲ (USP 1-Aug-2023) from the *Standard solution*

C_S = concentration of the corresponding Reference Standard in the *Standard solution* (mg/mL)

C_U = concentration of Dobutamine Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of ▲any▲ (USP 1-Aug-2023) unspecified impurities in the portion of Dobutamine Hydrochloride taken:

Result = (r_U/r_S) × (C_S/C_U) × 100

r_U = peak response of ▲any▲ (USP 1-Aug-2023) unspecified impurity from the *Sample solution*

r_S = peak response of dobutamine from the *Standard solution*

C_S = concentration of [USP Dobutamine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Dobutamine Hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Dopamine	0.33	0.5
Raspberry ketone	0.45	0.5
Dobutamine	1.00	—
Dobutamine related compound C	1.38	0.5
Any unspecified impurity	—	0.10
Total impurities	—	1.0

SPECIFIC TESTS

- [WATER DETERMINATION \(921\), Method I](#): NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.

Change to read:

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Dobutamine Hydrochloride RS](#)

[USP Dobutamine Related Compound C RS](#)

▲N-(3,4-Dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine hydrochloride.

C₂₁H₂₉NO₃ · HCl 379.93▲ (USP 1-Aug-2023)

[USP Dopamine Hydrochloride RS](#)

[USP Raspberry Ketone RS](#)

4-(4-Hydroxyphenyl)butan-2-one.

C₁₀H₁₂O₂ 164.20

Topic/Question	Contact	Expert Committee
DOBUTAMINE HYDROCHLORIDE	Documentary Standards Support	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 48(1)

Current DocID: GUID-0ADF040B-2AEC-400F-AA78-B75058D9FB78_6_en-US

DOI: https://doi.org/10.31003/USPNF_M27770_06_01

DOI ref: [9t58r](#)

OFFICIAL